Richard D. Carvajal, MD

Richard D. Carvajal, MD, is physician-in-chief and director of medical oncology at the Northwell Health Cancer Institute, and leads all hematology and medical oncology programs across Northwell’s cancer network.

Articles

A Close Look at Clinical Trials in Oncology and Beyond: Recruitment and Inclusion

January 30th 2025

In this episode, experts highlight the increasing push to simplify cancer trial eligibility criteria and improve diversity in participant enrollment.

A Close Look at Clinical Trials in Oncology and Beyond: State of Affairs and Industry Progress

January 30th 2025

In this episode, experts discuss progress in cancer clinical trials and the challenges posed by the increasing complexity of therapies and protocols.

A Close Look at Clinical Trials in Oncology and Beyond: Boosting Accessibility

January 30th 2025

In this episode, experts emphasize the importance of providing flexible clinical trial options, such as satellite sites and remote follow-ups.

A Close Look at Clinical Trials in Oncology and Beyond: Barriers to Participation

January 29th 2025

In this episode, experts discuss the challenges of increasing awareness and participation in clinical trials.

A Close Look at Clinical Trials in Oncology and Beyond: Incorporating Into Standard Care

January 28th 2025

In this episode, experts discuss the importance of integrating clinical trials as a standard of care, particularly in the realm of oncology.

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma

November 11th 2022

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma

March 10th 2016

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Community and the Care of Patients With Rare Cancers

April 6th 2015

Richard D. Carvajal, MD discusses the significance of researching, understanding, and improving outcomes for patients with rare cancers.

Dr. Carvajal on Vaccine Challenges in Cancer Therapy

April 6th 2015

Richard D. Carvajal, MD, Director, Experimental Therapeutics and Melanoma Service New York-Presbyterian Hospital/ Columbia University Medical Center, discusses the challenge of using vaccines for cancer therapy.

Dr. Carvajal on the Design of a Trial in Uveal Melanoma

September 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Dr. Richard D. Carvajal on the Investigation of Selumetinib

July 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

June 1st 2013

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.